hotspot -WSS

hotspot

author：Wikipedia 2025-10-01 04:10:10 - browse：1

Are venture capitalists OK? Are bolt-ons good for business? And when is it safe to say someone overpaid?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. We discuss how biotech’s downturn has made life difficult not just for startups but also the VCs they rely on for much-needed funding. We also take a look at Gilead Sciences’ struggle to turn itself into an oncology company and the latest biotech to get bought out by a major pharma firm.

For more on what we cover, here’s more on Gilead; here’s the news on Inhibrx; here’s the latest on biotech venture capital; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Elon Musk says Twitter has 'negative cash flow' and 'heavy debt'

entertainment

leisure time

WSS

Global childhood vaccinations edge closer to pre

What’s missing from the debate over nursing home staff minimums

American woman kidnapped in Mexico freed after 8 months in captivity: FBI

Top private equity targets in 2023: cardiology, clinical trials, lasers

Why police arrested suspected Gilgo Beach killer away from his house

Why Novartis is going to walk from its acquisition of MorphoSys

explore

hotspot

focus

In Memoriam: Notable people who died in 2023

Readout Newsletter: Amgen, Regeneron, BGI Group and more

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

American woman kidnapped in Mexico freed after 8 months in captivity: FBI

Trump demands the U.S. pay no more for drugs than other countries … again

Argenx drug significantly slows progression of nerve disorder

Novavax promises a turnaround & Lilly roils the obesity market

Congress: Eradicate hepatitis C and reduce the deficit

Hollywood unions extend contract negotiations for actors

Gene therapy for Afghan refugees’ infant will be fully covered

leisure time

Mike Pence clashes with Tucker Carlson in Iowa

Eli Lilly to acquire Versanis in heated race for weight loss drugs

Texas Medical Board asked to define abortion emergency exception

Bernie brings in new pharma CEOs to talk drug prices

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

AstraZeneca stays mum on Medicare drug pricing negotiations

Wikipedia

entertainment

leisure time

knowledge